Biotech Firm Polyrizon Eyes Majority Stake in Private Jet Operator Arrow Aviation
Event summary
- Polyrizon Ltd. signed a non-binding MOU to acquire 51% of Arrow Aviation for $5.8M.
- Arrow Aviation reported $19M in annual revenue and $3M in adjusted EBITDA.
- Transaction includes transfer of a $3.5M Hawker 800 aircraft and debt forgiveness via convertible notes.
- Definitive agreement expected within 30 days, pending due diligence.
The big picture
Polyrizon's move into private aviation marks a significant pivot from its biotech roots, targeting a high-growth sector with a profitable, established operator. The deal reflects a broader trend of non-industry players acquiring aviation assets to diversify revenue streams. With a $5.8M investment for a 51% stake, Polyrizon is betting on Arrow Aviation's $19M revenue and $3M EBITDA as a stable entry point into a market projected to expand rapidly.
What we're watching
- Execution Risk
- Whether Polyrizon can successfully navigate due diligence and close the deal within the 30-day timeline.
- Market Dynamics
- How the $41.38B private aviation market by 2030 will influence Polyrizon's valuation of Arrow Aviation.
- Strategic Fit
- The pace at which Polyrizon integrates Arrow Aviation's operations into its existing biotech-focused business model.
Related topics